Clinical Trials Logo

Hereditary Angioedema (HAE) clinical trials

View clinical trials related to Hereditary Angioedema (HAE).

Filter by:

NCT ID: NCT01541423 Completed - Clinical trials for Hereditary Angioedema (HAE)

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

Start date: May 11, 2012
Phase:
Study type: Observational

This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.

NCT ID: NCT01386658 Completed - Clinical trials for Hereditary Angioedema (HAE)

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

Start date: January 27, 2012
Phase: Phase 3
Study type: Interventional

HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with Hereditary Angioedema (HAE) during an initial acute attack.

NCT ID: NCT01095510 Completed - Clinical trials for Hereditary Angioedema (HAE)

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Start date: June 2, 2010
Phase: Phase 2
Study type: Interventional

The objectives of this study were to evaluate: (1) the dose response and (2) the pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) administration of CINRYZE for the treatment of acute angioedema attacks in children above and below 25 kg and less than 12 years of age with hereditary angioedema (HAE); and (3) to determine the safety and tolerability following IV administration of CINRYZE in this study population.

NCT ID: NCT01059526 Completed - Clinical trials for Hereditary Angioedema (HAE)

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Start date: February 1, 2010
Phase:
Study type: Observational

The objective of this study is to evaluate the formation of antibodies, the occurence of allergic reactions, and the risk of hypercoagulability and hypocoagulability in patients treated with KALBITOR (ecallantide).

NCT ID: NCT00457015 Completed - Clinical trials for Hereditary Angioedema (HAE)

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

Start date: April 1, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of DX-88 (ecallantide) versus placebo in the treatment of moderate to severe acute attacks of hereditary angioedema.

NCT ID: NCT00456508 Completed - Clinical trials for Hereditary Angioedema (HAE)

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

Start date: April 1, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of repeated doses of ecallantide in the treatment of acute attacks of hereditary angioedema and to allow HAE patients continued access to ecallantide. In addition, patients enrolled in DX-88/20 (EDEMA4) trial will be followed up and treated for subsequent attacks in this trial.

NCT ID: NCT00262080 Completed - Clinical trials for Hereditary Angioedema (HAE)

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Start date: December 31, 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.